Drug Profile
HS 130
Alternative Names: HS-130Latest Information Update: 09 Feb 2024
Price :
$50
*
At a glance
- Originator Heat Biologics
- Developer Scorpius Holdings
- Class Antineoplastics; Cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action OX40 ligand stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Suspended Solid tumours
Most Recent Events
- 06 Feb 2024 NightHawk Biosciences is now called Scorpius Holdings
- 15 May 2023 Suspended - Phase-I for Solid tumours (Combination therapy, In the elderly, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent, In adults) in USA (Intradermal)
- 16 Dec 2022 HS 130 is still in phase I trial for Solid tumours in USA (NightHawk Biosciences pipeline, December 2022)